|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
69,020,000 |
Market
Cap: |
106.29(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6003 - $1.92 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NGM Biopharmaceuticals is a biopharmaceutical company. Co. has five product candidates in the clinic, three wholly-owned by Co. (NGM707, NGM120 and aldafermin), one being progressed by its collaborator, Merck Sharp & Dohme Corp., or Merck (MK-3655) and one optionable by Merck (NGM621). Co.'s oncology product candidates include NGM707, NGM831, NGM438 and NGM120 and their related compounds. NGM621 was engineered to bind to, and be a long-acting inhibitor of, complement C3 with the treatment goal of reducing disease progression in patients with geographic atrophy, secondary to age-related macular degeneration. MK-3655 isin Phase 2b development for the treatment of nonalcoholic steatohepatitis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
94,704 |
3,933,628 |
Total Buy Value |
$0 |
$0 |
$64,854 |
$18,622,222 |
Total People Bought |
0 |
0 |
4 |
4 |
Total Buy Transactions |
0 |
0 |
10 |
76 |
Total Shares Sold |
0 |
0 |
0 |
85,082 |
Total Sell Value |
$0 |
$0 |
$0 |
$438,308 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kutzkey Tim |
Managing Partner |
|
2020-09-02 |
4 |
B |
$17.67 |
$487,604 |
D/D |
27,595 |
1,827,025 |
2.45 |
- |
|
Goeddel David V |
Managing Partner |
|
2020-09-01 |
4 |
B |
$17.64 |
$643,754 |
D/D |
36,494 |
1,799,430 |
3.92 |
- |
|
Kutzkey Tim |
Managing Partner |
|
2020-09-01 |
4 |
B |
$17.64 |
$643,754 |
D/D |
36,494 |
1,799,430 |
2.45 |
- |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2020-09-01 |
4 |
AS |
$17.62 |
$445,829 |
D/D |
(25,000) |
970,005 |
|
- |
|
Svennilson Peter |
Managing Partner |
|
2020-08-28 |
4 |
B |
$17.89 |
$467,555 |
D/D |
26,135 |
1,762,936 |
2.45 |
- |
|
Kutzkey Tim |
Managing Partner |
|
2020-08-28 |
4 |
B |
$17.89 |
$467,555 |
D/D |
26,135 |
1,762,936 |
2.45 |
- |
|
Svennilson Peter |
Managing Partner |
|
2020-08-27 |
4 |
B |
$17.79 |
$646,827 |
D/D |
36,359 |
1,736,801 |
2.45 |
- |
|
Kutzkey Tim |
Managing Partner |
|
2020-08-27 |
4 |
B |
$17.79 |
$646,827 |
D/D |
36,359 |
1,736,801 |
2.45 |
- |
|
Svennilson Peter |
General Partner |
|
2020-08-25 |
4 |
B |
$18.00 |
$1,800 |
D/D |
100 |
1,700,442 |
2.37 |
- |
|
Kutzkey Tim |
Managing Partner |
|
2020-08-25 |
4 |
B |
$18.00 |
$1,800 |
D/D |
100 |
1,700,442 |
2.37 |
- |
|
Svennilson Peter |
General Partner |
|
2020-08-24 |
4 |
B |
$17.96 |
$197,991 |
D/D |
11,024 |
1,700,342 |
2.45 |
- |
|
Kutzkey Tim |
Managing Partner |
|
2020-08-24 |
4 |
B |
$17.96 |
$197,991 |
D/D |
11,024 |
1,700,342 |
2.45 |
- |
|
Svennilson Peter |
General Partner |
|
2020-08-21 |
4 |
B |
$17.97 |
$131,558 |
D/D |
7,321 |
1,689,318 |
2.45 |
- |
|
Kutzkey Tim |
Managing Partner |
|
2020-08-21 |
4 |
B |
$17.97 |
$131,558 |
D/D |
7,321 |
1,689,318 |
2.45 |
- |
|
Svennilson Peter |
General Partner |
|
2020-08-17 |
4 |
B |
$17.89 |
$114,943 |
D/D |
6,425 |
1,681,997 |
2.45 |
- |
|
Kutzkey Tim |
Managing Partner |
|
2020-08-17 |
4 |
B |
$17.89 |
$114,943 |
D/D |
6,425 |
1,681,997 |
2.45 |
- |
|
Svennilson Peter |
General Partner |
|
2020-08-14 |
4 |
B |
$17.49 |
$664,498 |
D/D |
37,993 |
1,675,572 |
2.45 |
- |
|
Kutzkey Tim |
Managing Partner |
|
2020-08-14 |
4 |
B |
$17.49 |
$664,498 |
D/D |
37,993 |
1,675,572 |
2.45 |
- |
|
Svennilson Peter |
General Partner |
|
2020-08-13 |
4 |
B |
$17.89 |
$355,922 |
D/D |
19,895 |
1,637,579 |
2.45 |
- |
|
Kutzkey Tim |
Managing Partner |
|
2020-08-13 |
4 |
B |
$17.89 |
$355,922 |
D/D |
19,895 |
1,637,579 |
2.45 |
- |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2020-08-10 |
4 |
AS |
$19.02 |
$475,500 |
D/D |
(25,000) |
995,005 |
|
- |
|
Column Group Ii Gp, Lp |
General Partner |
|
2020-07-30 |
4 |
B |
$17.99 |
$13,169 |
D/D |
732 |
1,617,684 |
2.37 |
- |
|
Svennilson Peter |
General Partner |
|
2020-07-30 |
4 |
B |
$17.99 |
$13,169 |
D/D |
732 |
1,617,684 |
2.37 |
- |
|
Column Group Ii Gp, Lp |
General Partner |
|
2020-07-28 |
4 |
B |
$17.99 |
$73,849 |
D/D |
4,105 |
1,616,952 |
2.45 |
- |
|
Svennilson Peter |
General Partner |
|
2020-07-28 |
4 |
B |
$17.99 |
$73,849 |
D/D |
4,105 |
1,616,952 |
2.45 |
- |
|
499 Records found
|
|
Page 9 of 20 |
|
|